Posted on 2/27/19
Axial Biotherapeutics Raises $25 Million in Series B Financing
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative and neuropsychiatric diseases
Posted on 2/27/19
Novanta Announces Financial Results for the Fourth Quarter and Full Year 2018
BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and . . .
Posted on 2/27/19
Aprea Therapeutics Adds New Investor to Series C Financing
Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced that funds
Posted on 2/27/19
Blackstone Life Sciences Invests $250M In Anthos Therapeutics
Blackstone Life Sciences today announced the launch of Anthos Therapeutics Inc., a new biopharmaceutical company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients.As part . . .
Posted on 2/27/19
Epizyme Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today provided business and pipeline updates and reported fourth quarter and full year . . .
Posted on 2/26/19
Fresenius Medical Care Completes Acquisition Of NxStage Medical
Fresenius Medical Care, the world's largest provider of dialysis products and services, has successfully completed the acquisition of NxStage Medical, Inc.
Posted on 2/26/19
General Electric: $21 Billion Biopharma Sale Sends Shock Waves
SummaryGE's $21B biopharma sale is a masterstroke.It puts a sizable dent in GE's $110 billion debt load and improves its credit metrics.However, GE's debt likely remains . . .
Posted on 2/26/19
Sage Therapeutics Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an . . .
Posted on 2/26/19
Boston Scientific Completes $4.3 Billion Offering of Senior Notes
Boston Scientific Corporation (NYSE: BSX) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public offering consists of $850 million . . .
Posted on 2/25/19
Sage Therapeutics Proposes Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has . . .
Posted on 2/25/19
VBI Vaccines Provides Corporate Update
CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today . . .
Posted on 2/25/19
Rockland Immunochemicals and Cellaria Sign Worldwide Distribution Agreement
CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Cellaria, LLC, a scientific innovator that develops revolutionary new models for cancer and other diseases, today announced a . . .
Posted on 2/25/19
Thermo Fisher Scientific Launches New Dosimetry Monitoring Service
A new dosimetry monitoring service from Thermo Fisher Scientific enables medical and imaging facilities, dental offices, veterinary clinics, nuclear power plants, laboratories and other facilities with . . .
Posted on 2/25/19
Could Vertex Pharmaceuticals Be a Millionaire-Maker Stock?
Vertex Pharmaceuticals (NASDAQ:VRTX) has made lots of investors quite happy in recent years. The biotech stock has more than doubled over the past three years and . . .
Posted on 2/24/19
AbbVie and Voyager Therapeutics Announce Collaboration
AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological . . .
Posted on 2/22/19
Ocular Therapeutix Prices $37.5M Subordinated Convertible Debt Financing
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the . . .
Posted on 2/21/19
Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen
WALTHAM, Mass.--(BUSINESS WIRE)--Morphic Therapeutic (Morphic), a biotechnology company developing oral integrin therapies, announced today that it has entered into a research and development collaboration with Janssen . . .
Posted on 2/20/19
$100 Million Invested in Clinical Research for Impella
DANVERS, Mass.--(BUSINESS WIRE)--In a milestone for scientific research, Abiomed (NASDAQ: ABMD) has now invested more than $100 million over the past five years in clinical research . . .
Posted on 2/20/19
Torque Announces Clinical Trial Collaboration with Merck
Torque, a clinical-stage immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today that it has . . .
Posted on 2/20/19
IPO Update: Kaleido Biosciences Seeks $100 Million IPO
SummaryKaleido Biosciences has proposed terms for its U.S. IPO.The firm is developing treatment candidates for urea cycle disorders.It is still early stage, has no collaboration partners . . .
Posted on 2/20/19
Cognex Sees Slower Machine Vision Uptake at End of 2018
Shares of machine vision technologist Cognex (NASDAQ:CGNX) are rallying after the company reported a better-than-feared end to 2018. Revenue came in above management's expectations, wrapping up . . .
Posted on 2/19/19
Gamida Cell Announces Agreement with Editas Medicine
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, . . .
Posted on 2/19/19
Charles River Laboratories: Value Creation Continues
SummaryCharles River Labs reported a strong end to 2018 and made a nice deal.I like what management is doing, yet note that investors act with a . . .
Posted on 2/19/19
Charles River Laboratories To Acquire Citoxlab For EU CRO Services
Charles River Laboratories (CRL) announced it has made a binding offer to acquire Citoxlab for about $510 million in cash (€448 million).
Posted on 2/19/19
Cambrooke Therapeutics and Trovita Health Science Announce Strategic Alliance
AYER, Mass. & PHILADELPHIA--(BUSINESS WIRE)--Cambrooke Therapeutics, a member of The Ajinomoto Group, and Trovita Health Science, a specialty medical nutrition company, announce a joint marketing and . . .

